Walleye Capital’s Tourmaline Bio TRML Stock Holding History

Walleye Capital’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-78,907	Closed	-$1.01M	–	5879
2024 Q2	$1.01M	Buy	+78,907	New	+$1.27M	﹤0.01%	2835
2023 Q4	–	Sell	-26,247	Closed	-$738K	–	5531
2023 Q3	$738K	Sell	26,247 -4,213	-14%	-$123K	﹤0.01%	2494
2023 Q2	$926K	Buy	+30,460	New	+$778K	﹤0.01%	1913

Other funds holding TRML

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Walleye Capital's TRML Position: Q3 2024 in Review

Walleye Capital sold out of Tourmaline Bio (TRML) in Q3 2024, closing a stake of 78,907 shares — an estimated $1.01M sold.

Walleye Capital first reported a position in TRML in Q2 2023 and held it in 3 quarters. The position peaked at $1.01M in Q2 2024. 92 funds tracked by Wall St. Rank hold TRML as of Q3 2024.

Walleye Capital reported no remaining Tourmaline Bio position as of Q3 2024 after selling out during the quarter.
Walleye Capital sold 78,907 Tourmaline Bio shares in Q3 2024, an estimated $1.01M.
Walleye Capital first reported a position in Tourmaline Bio in Q2 2023 and held it in 3 quarters.
Walleye Capital's Tourmaline Bio position peaked at $1.01M in Q2 2024.
92 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.